Roche and Vernalis Group
Roche and Vernalis Group have signed a new agreement to collaborate on the r&d of novel drugs for the treatment of diabetes. Dr Jonathan Knowles, president of Global Pharma Research at Roche, said: 'Metabolic diseases represent a high unmet medical need. Both companies will focus on the discovery of novel molecular entities, acting through novel mechanisms of action, to target the improvement of the dysfunctional metabolic status in diabetic patients.'